瑞他鲁肽 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
== Career and research == Ly is a full professor in the Department of Chemistry at Carnegie Mellon University, where he leads a multidisciplinary research group focused on synthetic biomolecules, DNA and RNA recognition, and molecular engineering. His laboratory has published on electron transport mechanisms in double-stranded DNA and the development of conformationally preorganized peptide nucleic acids (PNAs). This includes designing molecules capable of recognizing double-helical DNA or RNA through Watson-Crick base pairing. He also developed bifacial (Janus) nucleic acid recognition elements designed to bind to sequences of double-stranded DNA and target secondary or tertiary structures of RNA. In the biotechnology sector, Ly has co-founded startups based on his research, including Xpeutics, Vera Therapeutics (formerly PNA Innovations), and NeuBase Therapeutics (formerly ChiraGen).
Excessive production of the thyroid hormones is called hyperthyroidism. Causes include Graves' disease, toxic multinodular goitre, solitary thyroid adenoma, inflammation, and a pituitary adenoma which secretes excess TSH. Another cause is excess iodine availability, either from excess ingestion, induced by the drug amiodarone, or following iodinated contrast imaging. Hyperthyroidism often causes a variety of non-specific symptoms including weight loss, increased appetite, insomnia, decreased tolerance of heat, tremor, palpitations, anxiety and nervousness. In some cases it can cause chest pain, diarrhoea, hair loss and muscle weakness. Such symptoms may be managed temporarily with drugs such as beta blockers. Long-term management of hyperthyroidism may include drugs that suppress thyroid function such as propylthiouracil, carbimazole and methimazole. Alternatively, radioactive iodine-131 can be used to destroy thyroid tissue: radioactive iodine is selectively taken up by thyroid cells, which over time destroys them. The chosen first-line treatment will depend on the individual and on the country where being treated. Surgery to remove the thyroid can sometimes be performed as a transoral thyroidectomy, a minimally invasive procedure. Surgery does however carry a risk of damage to the parathyroid glands and the recurrent laryngeal nerve, which innervates the vocal cords. If the entire thyroid gland is removed, hypothyroidism will inevitably result, and thyroid hormone substitutes will be needed.
Taisei Hokan Imperial Rescript on Education Imperial Rescript to Soldiers and Sailors Japanese Taiwan Japanese Korea Japanese nationalism List of political figures of Meiji Japan Meiji Memorial Picture Gallery Rising Sun Flag High Treason Incident Battle of Pyongyang (1894) Battle of Yalu River (1894) Battle of Jiuliancheng 1874 Japanese expedition to Taiwan Japanese invasion of Taiwan (1895) Ryukyu Disposition Shrine Consolidation Policy
==== Improving welfare ==== The key to improving welfare of marine cultured organisms is to reduce stress to a minimum, as prolonged or repeated stress can cause a range of adverse effects. Attempts to minimise stress can occur throughout the culture process. Understanding and providing required environmental enrichment can be vital for reducing stress and benefit aquaculture objects such as improved growth body condition and reduced damage from aggression. During grow-out it is important to keep stocking densities at appropriate levels specific to each species, as well as separating size classes and grading to reduce aggressive behavioural interactions. Keeping nets and cages clean can assist positive water flow to reduce the risk of water degradation. Not surprisingly disease and parasitism can have a major effect on fish welfare and it is important for farmers not only to manage infected stock but also to apply disease prevention measures. Prevention methods, such as vaccination, can also induce stress because of the extra handling and injection. Other methods include adding antibiotics to feed, adding chemicals into water for treatment baths and biological control, such as using cleaner wrasse to remove lice from farmed salmon. Many steps are involved in transport, including capture, food deprivation to reduce faecal contamination of transport water, transfer to transport vehicle via nets or pumps, plus transport and transfer to the delivery location.
X-ray diffraction studies of microcrystals revealed atomistic details of core region of amyloid, although only for simplified peptides having a length remarkably shorter than that of peptides or proteins involved in disease. The crystallographic structures show that short stretches from amyloid-prone regions of amyloidogenic proteins run perpendicular to the filament axis, consistent with the "cross-β" feature of amyloid structure. They also reveal a number of characteristics of amyloid structures – neighboring β-sheets are tightly packed together via an interface devoid of water (therefore referred to as dry interface), with the opposing β-strands slightly offset from each other such that their side-chains interdigitate. This compact dehydrated interface created was termed a steric-zipper interface. There are eight theoretical classes of steric-zipper interfaces, dictated by the directionality of the β-sheets (parallel and anti-parallel) and symmetry between adjacent β-sheets. A limitation of X-ray crystallography for solving amyloid structure is represented by the need to form microcrystals, which can be achieved only with peptides shorter than those associated with disease. Although bona fide amyloid structures always are based on intermolecular β-sheets, different types of "higher order" tertiary folds have been observed or proposed. The β-sheets may form a β-sandwich, or a β-solenoid which may be either β-helix or β-roll. Native-like amyloid fibrils in which native β-sheet containing proteins maintain their native-like structure in the fibrils have also been proposed.
Sources: en.wikipedia.org
A ligament is a small band of dense, white, fibrous elastic tissue. Ligaments connect the ends of bones together in order to form a joint. Most ligaments limit dislocation, and prevent certain movements, such as hyperextension and hyperflexion, which may lead to breaks. An enthesis is the connective tissue that attaches tendons and ligaments to bones. Fascia (from Latin fascia 'band') is a generic term for macroscopic membranous bodily structures. The human skeleton may be divided into two distinct divisions: the axial skeleton, which includes the vertebral column, and the appendicular skeleton.
Community design and reliance on automobiles have been linked to obesity risk. A walkability index developed for Atlanta-area communities found that residents of the most walkable neighborhoods were 2.4 times more likely to get recommended amounts of physical activity than those in the least walkable areas. A follow-up study found that a 5% increase in a community's walkability index was associated with a 32.1% increase in time spent walking or biking and a 0.23-point reduction in BMI. Worldwide there has been a large shift towards less physically demanding work, and currently at least 30% of the world's population gets insufficient exercise. This is primarily due to increasing use of mechanized transportation and a greater prevalence of labor-saving technology in the home. In children, there appear to be declines in levels of physical activity (with particularly strong declines in the amount of walking and physical education), likely due to safety concerns, changes in social interaction (such as fewer relationships with neighborhood children), and inadequate urban design (such as too few public spaces for safe physical activity). World trends in active leisure time physical activity are less clear. The World Health Organization indicates people worldwide are taking up less active recreational pursuits, while research from Finland found an increase and research from the United States found leisure-time physical activity has not changed significantly. Physical activity in children may not be a significant contributor.
August Wilhelm joined the conservative nationalist veterans group Der Stahlhelm (English: "The Steel helmet"). In the following years he had increasing contact with the NSDAP. He joined the Nazi Party on 1 April 1930, whereupon he received the low membership number 24, for symbolic reasons. In November 1931, he was accepted into the paramilitary Sturmabteilung (SA) with the rank of Standartenführer. His involvement with the NSDAP and his adoration of Adolf Hitler made August Wilhelm often the subject of mockery by the left-wing press (who gave him the nickname Braunhemdchen Auwi, or "Auwi the Little Brown Shirt"), politicians (French Ambassador André François-Poncet called him Hanswurst "Hans the Brown Sausage") and from the National Socialists themselves (Joseph Goebbels referred to him as a "good-natured but slightly gormless boy"). As a representative of the erstwhile Hohenzollern dynasty, August Wilhelm was deliberately used by the party to gain votes in elections: he was elected as its lead candidate for the Landtag of Prussia in April 1932, and retained his seat until the Landtag's dissolution in October 1933. At the same time, he was appointed an election speaker alongside Hitler, whom he accompanied on flights across Germany. Through his appearances at the party's mass rallies, he addressed himself to sections of the population that were lukewarm towards National Socialism and convinced them "that Hitler was not a threat, but a benefactor of the German people and the German Empire".
== Structure == The GSTK1 enzyme is a homodimer and, like all GSTs, it contains a TRX-like domain and a helical domain. However, the GSTK1 is substantially different in its secondary structure compared to the other GSTs. The helical domain has been observed to be placed between the βαβ and ββα motifs of the TRX-like domain, rather than the TRX-like domain and the C-terminal helical domain being connected together by a short linker of alpha-helixes as normally seen in GSTs. Also, the GSTK1 dimer employs a butterfly shape and not a V-shaped crevice like in the other classes. As for the GSTK1 gene, it is ~5 kb long, has eight exons, is located on chromosome 7q34, and includes an initiator element at the transcription start site instead of a TATA or a CCAAT box.
Sources: en.wikipedia.org
The predicted half-lives for these nuclides often greatly exceed the estimated age of the universe, and in fact, there are also 31 known radionuclides (see primordial nuclide) with half-lives longer than the age of the universe. The total of all known nuclides, of which most have been created only artificially, is several thousand, of which 987 are stable or have a half-life longer than one hour; see List of nuclides.
==== Regional hubs ==== UPS has five regional hubs in the Asia-Pacific region, located in Hong Kong, Japan, Korea, Malaysia, and Thailand. These hubs serve as major sorting and distribution centers for packages moving within and between regions.
Hoffman alleged Edwards employed monopoly practices in breach of the Sherman Act because it had 70% share of the integrated vacuum pump frame systems market in the US and suppressed competition, imposing non-compete covenants on its suppliers and engaged in employee intimidation; customer threats, and bad faith litigation. In May 2021, Edwards was granted a partial, interim injunction against Hoffman selling a bellows component. Judgement declined to accept Edwards' application of Noerr–Pennington doctrine to dismiss Hoffman's anti competition counterclaim. In June 2022, the parties entered into a Confidential Settlement Agreement through which both parties' claims were dismissed with prejudice.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。